Famciclovir in Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Famciclovir
Human herpesvirus 1 DNA polymerase inhibitor
What it measured
Main measures
The primary outcome of this study will be suppression of EBV shedding in saliva. Shedding is defined as EBV DNA levels in saliva >5.8 copies/ml.
Immune response
Other measures (1)
There are no secondary endpoints for this study. All other endpoints are exploratory.
Who could take part
MS (type not specified)
Inclusion: People with MS aged over 18 who are taking Natalizumab (Tysabri) will be eligible for inclusion in this study. Participants must be able to provide informed consent to take part in this study. Exclusion: People with MS who are taking interferon-beta preparations or teriflunomide will not be eligible for this study.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary aim of this study is to explore the effect of famciclovir (500mg twice daily) on Epstein Barr virus shedding in the saliva of people with MS.
Loading reviews and guidelines…
Related trials
- TARGET-EBV in MS: Targeting Epstein Barr Virus with Tenof…
Phase 2 · Not yet recruiting
Still running
- Effects of Antiviral Therapies on Epstein-Barr Virus Repl…
Phase 2 · Enrolling by invitation
Still running
- Famciclovir in Multiple Sclerosis
Phase 2 · Status unknown
Result in a paper, not read yet
- Single Ascending Doses Study With GNbAC1 in Healthy Male …
Phase 1 · Completed
Result in a paper, not read yet
- First-in-Human Study With GNbAC1 in Healthy Volunteers
Phase 1 · Completed
Result in a paper, not read yet
History
Started
Jun 2019
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error